The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Abbott Introduces Biothreat Assay for PLEX-IDâ„¢ System

February 7, 2011 7:33 am | by Bio-Medicine.Org | News | Comments

WASHINGTON, Feb. 7, 2011 /- Abbott (NYSE: ABT ) announced today that it has introduced the PLEX-ID™ Biothreat Assay, which is designed to detect and distinguish 17 different biothreat pathogens.  This assay enables rapid and accurate detection of potentially dangerous...


Prize4Life gives $1M ALS award to Mass. doctor, entrepreneur

February 7, 2011 6:35 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Prize4Life, a Cambridge non-profit focused on advancing research into cures for ALS, has awarded a prize of $1 million to Dr. Seward Rutkove for his discovery of a new biomarker for ALS.


Expanding drug development horizons: Receptor behaviors observed in living cell membranes

February 7, 2011 5:36 am | by EurekAlert | News | Comments

(Institute for Integrated Cell-Material Sciences, Kyoto University) Unprecedented single molecule imaging movies of living cell membranes, taken by a research team based at Kyoto University and the University of New Mexico, have clarified a decades-old enigma surrounding receptor...


Danaher agrees to buy Beckman Coulter for $5.87B

February 7, 2011 4:45 am | by The Associated Press | News | Comments

Medical and industrial instruments maker Danaher Corp. said Monday it agreed to buy medical testing instrument maker Beckman Coulter for about $5.87 billion.Beckman Coulter Inc. makes products that simplify and automate biomedical testing. It will become part of Danaher's life sciences and...

Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Contact Cooling System for Aesthetic Use

February 7, 2011 4:36 am | by U.S. Food & Drug Administration | News | Comments

This guidance document was developed as a special control guidance to support the classification of the contact cooling system for aesthetic use into class II (special controls). The device is intended to apply cooling to the body to achieve temporary...

Federal Register: Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee; Notice of Meeting

February 7, 2011 4:35 am | by U.S. Food & Drug Administration | News | Comments

On March 8 and 9, 2011, the committee will discuss and make recommendations on scientific issues concerning direct to consumer (DTC) genetic tests that make medical claims.

Amarin to Present at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference

February 7, 2011 4:34 am | by Bio-Medicine.Org | News | Comments

MYSTIC, Conn. and DUBLIN, Feb. 7, 2011 /- Amarin Corporation plc (Nasdaq: AMRN ) today announced that it is scheduled to participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference on Wednesday, February 16, 2011. Amarin's participation includes both a panel...


UrgentRx Launches Line of Innovative and Portable, Fast-Acting Medications Across Colorado

February 7, 2011 4:33 am | by Bio-Medicine.Org | News | Comments

DENVER, Feb. 7, 2011 /- Colorado start-up, UrgentRx , today announced the launch of a new line of fast-acting, powdered medications in convenient credit card-sized packets, including UrgentRx Aspirin to Go , a life-saving product specifically developed as heart attack first aid....


Cancer Patients in Bangladesh Gain Access to Advanced RapidArc Radiotherapy Treatments from Varian Medical Systems

February 7, 2011 4:33 am | by Bio-Medicine.Org | News | Comments

DHAKA, Bangladesh, Feb. 7, 2011 /- Cancer patients in Bangladesh, a country of 160 million people served by just 11 modern radiotherapy linear accelerators, now have access to advanced radiotherapy technology from Varian Medical Systems (NYSE: VAR). Treatments using fast and efficient...


Patheon appoints James Mullen as chief executive officer effective immediately

February 7, 2011 3:45 am | by The Associated Press | News | Comments

Patheon Inc. (TSX:PTI) appoints James Mullen as chief executive officer effective immediately. Mullen formerly headed Biogen Idec Inc.

Henry Schein to Present at the UBS 21st Annual Global Healthcare Services Conference

February 7, 2011 3:33 am | by Bio-Medicine.Org | News | Comments

MELVILLE, N.Y., Feb. 7, 2011 /- Henry Schein, Inc., (Nasdaq: HSIC ), the largest provider of health care products and services to office-based practitioners, announced today that Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein, and Steven Paladino, the Company's...


FTC Grants Early Termination of Waiting Period Under Hart-Scott-Rodino Act

February 7, 2011 3:32 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Feb. 7, 2011 /- Genoptix, Inc. (Nasdaq: GXDX ) announced today that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act") applicable to the cash tender offer by...


Humana posts big drop in 4Q earnings

February 7, 2011 1:45 am | by The Associated Press | News | Comments

Health insurer Humana Inc. is reporting a 57 percent drop in fourth-quarter earnings due partly to expenses associated with its Medicare Advantage plan and the start of a prescription drug offering in which it's partners with Wal-Mart.The company said Monday that it had $1.02 per share of...

Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery

February 6, 2011 11:35 pm | by Bio-Medicine.Org | News | Comments

BLUE BELL, Pa., Feb. 7, 2011 /- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its new generation DNA vaccine delivery technology, which provides the powerful...


Data on DermTech's Non-invasive Test for Melanoma Are Published in the British Journal of Dermatology

February 6, 2011 11:35 pm | by Bio-Medicine.Org | News | Comments

LA JOLLA, Calif., Feb. 7, 2011 /- DermTech International, Inc., a biotechnology company dedicated to bringing genomic medicine to dermatologists, today announced that the discovery data on its new genomic assay for melanoma have been published in the British Journal of Dermatology....



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.